Piper Sandler has resumed coverage of Supernus Pharmaceuticals with an 'overweight' rating and a $47 price target, driven by the anticipated benefits of its merger with Indivior. The analyst highlights enhanced business development capabilities and strong revenue projections for key products, suggesting a positive outlook for the combined entity.
Piper Sandler has resumed coverage of Supernus Pharmaceuticals, upgrading its outlook to 'overweight' with a $47 price target. This positive re-evaluation is directly linked to the announced merger with Indivior, which the analyst believes will significantly enhance the combined company's business development and M&A capabilities. The firm projects strong revenue concentration from key products and anticipates EBITDA exceeding $1 billion by 2027, providing substantial financial flexibility. This news is a positive catalyst for Supernus (SUPN) and its merger partner Indivior (INDV), as it signals Wall Street's confidence in the strategic rationale and financial prospects of the combined entity. Short-term, this could lead to increased investor interest and upward price momentum for SUPN, while long-term, the successful integration and execution of the combined strategy will be key. A primary opportunity for traders lies in the potential for re-rating as the market fully digests the synergistic benefits outlined by Piper Sandler.